Filing Flows › Agios Pharmaceuticals (AGIO) › Q2 2026 › vs Q1 2026
Agios Pharmaceuticals (AGIO) Q2 2026 vs Q1 2026 (quarter over quarter)
Agios Pharmaceuticals's revenue rose $24.0M (+116%) from $20.7M in Q1 2026 to $44.7M in Q2 2026.
Agios Pharmaceuticals, Q2 2026: revenue $44.7M (+259% year over year), operating margin -247.1%, net loss $101M, operating cash flow −$57.3M. The chart draws each line against Q1 2026, the increases inside each band.
Every line
| Line | Q2 2026 | Q1 2026 | Change | % |
|---|---|---|---|---|
| Revenue | $44.7M | $20.7M | $24.0M | +116% |
| Other income, net | $9.8M | $10.9M | −$1.1M | -10% |
| Net loss | $101M | $99.1M | $1.6M | +2% |
| Costs & expenses | $155M | $131M | $24.5M | +19% |
| Operating costs | $155M | $131M | $24.5M | +19% |
| Cost of revenue | $3.0M | $1.3M | $1.7M | +127% |
| Research & development | $101M | $81.1M | $19.6M | +24% |
| SG&A | $51.5M | $48.3M | $3.2M | +7% |
| Operating cash sources | $101M | $99.1M | $1.6M | +2% |
| Share-based compensation | $15.9M | $15.5M | $400K | +3% |
| Working capital & other | $27.4M | −$35.4M | $62.8M | — |
| Cash used in operations | $57.3M | $119M | −$61.6M | -52% |
| Net loss absorbed | $101M | $99.1M | $1.6M | +2% |
Questions
How much did Agios Pharmaceuticals's revenue grow quarter over quarter in Q2 2026?
Agios Pharmaceuticals's revenue rose $24.0M (+116%) from $20.7M in Q1 2026 to $44.7M in Q2 2026.